ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
ExcelFemale
HRT in Women
Medherant transdermal patch development collaboration with Bayer
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 279581" data-attributes="member: 13851"><p>[URL unfurl="true"]https://www.medherant.co.uk/news/medherant-transdermal-patch-development-collaboration-bayer[/URL]</p><p></p><p></p><p>Coventry, UK (25 March 2024): <em>Medherant Limited (“Medherant”) announces that it has <strong>entered into a Development Collaboration Agreement with Bayer for the development of a transdermal patch product for delivery of an already-approved oral medicine.</strong></em></p><p><em><strong></strong></em></p><p><em><strong>For the last 3 years, Medherant and Bayer have worked on formulation development for this product, utilising Medherant’s expertise in the use of laboratory models for assessment of transdermal drug delivery with the <u>TEPI Patch® technology</u>.</strong></em></p><p><em></em></p><p><em>The Development and Collaboration Agreement marks the movement of the collaboration to the next phase of development as <strong>Medherant and Bayer move the programme to non-clinical studies and approach technology transfer for patch production at Medherant’s contract manufacturing partner</strong>. Medherant is responsible for leading the programme through to completion of the clinical proof of concept study.</em></p><p><em></em></p><p><em><strong>Following a successful outcome to the clinical proof of concept study, Medherant and Bayer expect to negotiate a definitive licence agreement to enable Bayer to complete the development programme and pursue commercialisation of this novel TEPI Patch transdermal drug delivery product. </strong>Medherant anticipates that the licence agreement will provide for payments to Medherant through the development and registration process as well as royalties payable on sales of this product.</em></p><p><em></em></p><p><em><strong>Bayer is committed to transforming self-care by offering precision health solutions to enable consumers to better understand and make informed decisions about their own personal health and lifestyle choices.</strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 279581, member: 13851"] [URL unfurl="true"]https://www.medherant.co.uk/news/medherant-transdermal-patch-development-collaboration-bayer[/URL] Coventry, UK (25 March 2024): [I]Medherant Limited (“Medherant”) announces that it has [B]entered into a Development Collaboration Agreement with Bayer for the development of a transdermal patch product for delivery of an already-approved oral medicine. For the last 3 years, Medherant and Bayer have worked on formulation development for this product, utilising Medherant’s expertise in the use of laboratory models for assessment of transdermal drug delivery with the [U]TEPI Patch® technology[/U].[/B] The Development and Collaboration Agreement marks the movement of the collaboration to the next phase of development as [B]Medherant and Bayer move the programme to non-clinical studies and approach technology transfer for patch production at Medherant’s contract manufacturing partner[/B]. Medherant is responsible for leading the programme through to completion of the clinical proof of concept study. [B]Following a successful outcome to the clinical proof of concept study, Medherant and Bayer expect to negotiate a definitive licence agreement to enable Bayer to complete the development programme and pursue commercialisation of this novel TEPI Patch transdermal drug delivery product. [/B]Medherant anticipates that the licence agreement will provide for payments to Medherant through the development and registration process as well as royalties payable on sales of this product. [B]Bayer is committed to transforming self-care by offering precision health solutions to enable consumers to better understand and make informed decisions about their own personal health and lifestyle choices.[/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
ExcelFemale
HRT in Women
Medherant transdermal patch development collaboration with Bayer
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top